Nuvation Bio Partners With Thermo Fisher for U.S. Production of IBTROZI
NEW YORK, May 13, 2026 Nuvation Bio announced a strategic collaboration with Thermo Fisher Scientific to establish U.S.-based manufacturing...
taletrectinib
Advertisement
Nuvation Bio Expands IBTROZI FDA Lung Cancer Filing
NEW YORK, May 6, 2026 Nuvation Bio Inc., a global oncology-focused biopharmaceutical company, has announced that the U.S. Food...
Nuvation Bio Strengthens Oncology Pipeline with IBTROZI and Safusidenib Advances
New York, USA, April 21,2026 In a major development in global oncology drug innovation, Nuvation Bio Inc. has highlighted...
Eisai Nuvation Taletrectinib EMA MAA Validation
Tokyo & New York – March 27, 2026 Eisai and Nuvation Bio announced that the European Medicines Agency (EMA)...
Advertisement
